Rigel Pharmaceuticals (RIGL) EBIT (2010 - 2026)

Rigel Pharmaceuticals' EBIT history runs 17 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• On a quarterly basis, EBIT fell 6.95% year-over-year to $11.9 million in Q1 2026; TTM through Mar 2026 was $124.6 million, a 183.58% increase from a year earlier, with the FY2025 full-year figure at $125.5 million, up 418.63% from the prior year.
• EBIT slipped to $11.9 million in Q1 2026 per RIGL's latest filing, from $23.2 million in the prior quarter.
• Across five years, EBIT topped out at $61.1 million in Q2 2025 and bottomed at -$26.3 million in Q1 2022.
• The 5-year median for EBIT is $2.0 million (2023), against an average of $5.0 million.
• Across the five-year window, EBIT plunged 162.89% in 2022 and soared 13569.57% in 2025, its largest moves.
• Year by year, EBIT stood at $2.1 million in 2022, then slipped by 5.44% to $2.0 million in 2023, then surged by 747.15% to $16.7 million in 2024, then surged by 39.12% to $23.2 million in 2025, then tumbled by 48.71% to $11.9 million in 2026.
• Per Business Quant, the three latest RIGL EBIT figures stand at $11.9 million (Q1 2026), $23.2 million (Q4 2025), and $28.4 million (Q3 2025).